{"transactions":[{"id":4637630,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-10-08T01:00:10.000Z","date":"2026-10-05","kind":"grant","planned":false,"acquired":true,"shares":64000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027."}],"balance_after":64000,"derivative":{"exercise_price":3.75,"expiration_date":"2036-10-05","underlying":"Common Stock","underlying_shares":64000},"source":{"system":"sec-edgar","filing":"0001193125-26-417235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1657768/000119312526417235/ownership.xml","form_type":"4"}},{"id":4637629,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-08T01:00:10.000Z","date":"2026-10-05","kind":"grant","planned":false,"acquired":true,"shares":10700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027."}],"balance_after":30779,"source":{"system":"sec-edgar","filing":"0001193125-26-417235","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657768/000119312526417235/ownership.xml","form_type":"4"}},{"id":687690,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T01:00:06.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":3864,"price":6.01,"value":23222.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 11, 2026, the reporting person sold 3,864 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.01 to $6.03 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":20079,"source":{"system":"sec-edgar","filing":"0001193125-26-349961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526349961/ownership.xml","form_type":"4"}},{"id":827144,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Shares","published_at":"2026-03-26T20:15:13.000Z","date":"2026-03-23","kind":"exercise","planned":false,"acquired":false,"shares":3901348,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. (\"SNBL USA\") and Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026."},{"field":"date","element":"transactionDate","label":"F1","text":"The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. (\"SNBL USA\") and Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. (\"SNBL USA\") and Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes (i) 2,100,000 shares held by SNBL USA and (ii) 1,801,348 shares held by SNBL."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. (\"SNBL USA\") and Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. (\"SNBL USA\") and Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the \"Act\"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3901348},"source":{"system":"sec-edgar","filing":"0001193125-26-126276","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526126276/ownership.xml","form_type":"4"}},{"id":827143,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-26T20:15:13.000Z","date":"2026-03-23","kind":"exercise","planned":false,"acquired":true,"shares":3901348,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. (\"SNBL USA\") and Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. (\"SNBL USA\") and Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes (i) 2,100,000 shares held by SNBL USA and (ii) 1,801,348 shares held by SNBL."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of (i) 6,107,593 shares held by SNBL USA and (ii) 3,498,815 shares held by SNBL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the \"Act\"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL."}],"balance_after":9606408,"source":{"system":"sec-edgar","filing":"0001193125-26-126276","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526126276/ownership.xml","form_type":"4"}},{"id":1067505,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-08-14T00:00:11.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":76200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026."}],"balance_after":76200,"derivative":{"exercise_price":8.105,"expiration_date":"2030-08-11","underlying":"Ordinary Shares","underlying_shares":76200},"source":{"system":"sec-edgar","filing":"0000950170-25-108289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000095017025108289/ownership.xml","form_type":"4"}},{"id":1067504,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-14T00:00:11.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":12700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026."}],"balance_after":5729003,"source":{"system":"sec-edgar","filing":"0000950170-25-108289","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000095017025108289/ownership.xml","form_type":"4"}},{"id":1071986,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-08T00:00:06.000Z","date":"2025-08-05","kind":"sale","planned":true,"acquired":false,"shares":4872,"price":8.75,"value":42630.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 5, 2025, the reporting person sold 4,872 ordinary shares solely to cover taxes associated with the vesting of restricted share units on August 5, 2025. These sales were made pursuant to a 10b5-1 Trading Plan."}],"balance_after":5716303,"source":{"system":"sec-edgar","filing":"0000950170-25-105353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000095017025105353/ownership.xml","form_type":"4"}},{"id":1433328,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Share Option (right to buy)","published_at":"2024-08-14T22:00:03.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":32230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025."}],"balance_after":32230,"derivative":{"exercise_price":5.37,"expiration_date":"2029-08-12","underlying":"Ordinary Shares","underlying_shares":32230},"source":{"system":"sec-edgar","filing":"0000950170-24-097283","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000095017024097283/ownership.xml","form_type":"4"}},{"id":1433327,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2024-08-14T22:00:03.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":16115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025."}],"balance_after":5721175,"source":{"system":"sec-edgar","filing":"0000950170-24-097283","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000095017024097283/ownership.xml","form_type":"4"}},{"id":1811685,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Share Option (right to buy)","published_at":"2023-08-10T00:00:28.000Z","date":"2023-08-07","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2024 annual general meeting or August 7, 2024."}],"balance_after":45000,"derivative":{"exercise_price":4.58,"expiration_date":"2028-08-07","underlying":"Ordinary Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-23-017915","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924323017915/doc4.xml","form_type":"4"}},{"id":1862371,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T16:44:09.000Z","date":"2023-06-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.46,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-23-014896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924323014896/doc4.xml","form_type":"4"}},{"id":1862370,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T16:44:09.000Z","date":"2023-06-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":4.6,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-014896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924323014896/doc4.xml","form_type":"4"}},{"id":1862369,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T16:44:09.000Z","date":"2023-06-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the \"Shares\") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the \"Offer Price\"), that is outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":26.99,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-23-014896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924323014896/doc4.xml","form_type":"4"}},{"id":1862368,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2023-06-08T16:44:09.000Z","date":"2023-06-06","kind":"purchase","planned":false,"acquired":true,"shares":22053581,"price":0.91,"value":20068758.71,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All of the shares were cancelled on June 8, 2023 pursuant to the terms of that certain Agreement and Plan of Merger, dated April 16, 2023, by and between the Issuer, Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation (\"SNBL\"), and SNBL23 Merger Sub, Inc. (\"Merger Sub\"), a Delaware corporation (the \"Merger Agreement\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Shares acquired by Merger Sub, upon acceptance of all shares validly tendered and not validly withdrawn pursuant to the tender offer by Merger Sub and SNBL, pursuant to the Merger Agreement, for any and all outstanding shares of Satsuma common stock pursuant to that certain Offer to Purchase, dated May 5, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All of the shares were cancelled on June 8, 2023 pursuant to the terms of that certain Agreement and Plan of Merger, dated April 16, 2023, by and between the Issuer, Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation (\"SNBL\"), and SNBL23 Merger Sub, Inc. (\"Merger Sub\"), a Delaware corporation (the \"Merger Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by SNBL and SNBL U.S.A., Ltd., a wholly owned subsidiary of SNBL. Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the \"Act\"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities."}],"balance_after":24847694,"source":{"system":"sec-edgar","filing":"0000899243-23-014896","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924323014896/doc4.xml","form_type":"4"}},{"id":2091138,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-09T16:11:27.000Z","date":"2022-06-03","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting."}],"balance_after":30000,"derivative":{"exercise_price":3.46,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001567619-22-021461","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000156761922021461/doc1.xml","form_type":"4/A","original_submission_date":"2022-06-07"}},{"id":2180640,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Share Option (right to buy)","published_at":"2022-08-18T00:00:55.000Z","date":"2022-08-15","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2023 annual general meeting or August 15, 2023."}],"balance_after":21000,"derivative":{"exercise_price":3.5,"expiration_date":"2027-08-15","underlying":"Ordinary Shares","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000899243-22-029096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924322029096/doc4.xml","form_type":"4"}},{"id":2240209,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-07T17:36:57.000Z","date":"2022-06-03","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting."}],"balance_after":30000,"derivative":{"exercise_price":3.46,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001567619-22-012473","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000156761922012473/doc1.xml","form_type":"4"}},{"id":2597192,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Share Option (right to buy)","published_at":"2021-08-18T22:11:33.000Z","date":"2021-08-16","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 12.5% of the shares in equal quarterly installments over the two-year period following the grant date on August 16, 2021."}],"balance_after":42000,"derivative":{"exercise_price":5.97,"expiration_date":"2026-08-16","underlying":"Ordinary Shares","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000899243-21-033527","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924321033527/doc4.xml","form_type":"4"}},{"id":2955265,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-07T18:05:49.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full and become exercisable on the day immediately preceding the 2022 Annual Meeting."}],"balance_after":20000,"derivative":{"exercise_price":4.6,"expiration_date":"2030-12-03","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001567619-20-020722","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000156761920020722/doc1.xml","form_type":"4"}},{"id":3050660,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Share Option (right to buy)","published_at":"2020-08-20T22:33:03.000Z","date":"2020-08-18","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021."}],"balance_after":10500,"derivative":{"exercise_price":9.13,"expiration_date":"2025-08-18","underlying":"Ordinary Shares","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0000899243-20-023087","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924320023087/doc4.xml","form_type":"4"}},{"id":3109163,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-16T19:23:32.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the first Annual Meeting following the date of grant and (ii) the  first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":26.99,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001567619-20-012248","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000156761920012248/doc1.xml","form_type":"4"}},{"id":3412423,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-09-17T16:05:17.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":307110,"ownership":{"direct":false,"nature":"See FN"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\").  Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL.  Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the \"Act\"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":307110},"source":{"system":"sec-edgar","filing":"0000899243-19-023732","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924319023732/doc4.xml","form_type":"4"}},{"id":3412422,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-09-17T16:05:17.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":33741,"ownership":{"direct":false,"nature":"See FN"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\").  Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL.  Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the \"Act\"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":33741},"source":{"system":"sec-edgar","filing":"0000899243-19-023732","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924319023732/doc4.xml","form_type":"4"}},{"id":3412421,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2019-09-17T16:05:17.000Z","date":"2019-09-17","kind":"purchase","acquired":true,"shares":233333,"price":15,"value":3499995.0,"ownership":{"direct":false,"nature":"See FN"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"SNBL USA, Ltd., a subsidiary of SNBL, purchased an additional 233,333 shares of issuer's common stock in connection with the initial public offering at the offering price of $15.00 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\").  Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL.  Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the \"Act\"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities."}],"balance_after":1561719,"source":{"system":"sec-edgar","filing":"0000899243-19-023732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924319023732/doc4.xml","form_type":"4"}},{"id":3412420,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2019-09-17T16:05:17.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":307110,"ownership":{"direct":false,"nature":"See FN"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\").  Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL.  Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the \"Act\"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities."}],"balance_after":1328386,"source":{"system":"sec-edgar","filing":"0000899243-19-023732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924319023732/doc4.xml","form_type":"4"}},{"id":3412419,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2019-09-17T16:05:17.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":33741,"ownership":{"direct":false,"nature":"See FN"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Shin Nippon Biomedical Laboratories, Ltd. (\"SNBL\").  Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL.  Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the \"Act\"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities."}],"balance_after":1021276,"source":{"system":"sec-edgar","filing":"0000899243-19-023732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000089924319023732/doc4.xml","form_type":"4"}},{"id":3435741,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Share Option (right to buy)","published_at":"2019-08-16T20:20:28.000Z","date":"2019-08-15","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020."}],"balance_after":10500,"derivative":{"exercise_price":20.34,"expiration_date":"2024-08-15","underlying":"Ordinary Shares","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0000899243-19-021963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924319021963/doc4.xml","form_type":"4"}},{"id":3842967,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Share Option (right to buy)","published_at":"2018-08-16T00:08:38.000Z","date":"2018-08-13","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019."}],"balance_after":9000,"derivative":{"exercise_price":46.7,"expiration_date":"2023-08-13","underlying":"Ordinary Shares","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000899243-18-022512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924318022512/doc4.xml","form_type":"4"}},{"id":4230184,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Share Option (right to buy)","published_at":"2017-08-17T20:19:45.000Z","date":"2017-08-10","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 10, 2018."}],"balance_after":9000,"derivative":{"exercise_price":18.1,"expiration_date":"2022-08-10","underlying":"Ordinary Shares","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000899243-17-020602","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924317020602/doc4.xml","form_type":"4"}},{"id":4557125,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23620,"kind":"person","name":"TAKANASHI KEN","position":1,"cik":"0001657768","reported_name":"TAKANASHI KEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Share Option (right to buy)","published_at":"2016-11-14T23:24:07.000Z","date":"2016-11-10","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on November 10, 2017."}],"balance_after":9000,"derivative":{"exercise_price":36.43,"expiration_date":"2021-11-10","underlying":"Ordinary Shares","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000899243-16-033374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924316033374/doc4.xml","form_type":"4"}}]}